Key facts
- This page summarizes David J. Grainger's Form 4 filing for Centessa Pharmaceuticals plc (CNTA).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 01 Feb 2022, 19:15.
David J. Grainger - 28 Jan 2022 Form 4 Insider Report for Centessa Pharmaceuticals plc (CNTA)
- Reporting relationship
- Chief Innovation Officer
- Issuer ticker
- CNTA
- Reported as of
- 28 Jan 2022
- Net transaction value
- +$248,754
- SEC form
- 4
- Accepted by SEC
- 01 Feb 2022, 19:15:00 UTC
- Prior SEC filing
- 02 Nov 2021
- Next SEC filing
- 03 Feb 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Marella Thorell, attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Filing notes and source
Key filing fact
David J. Grainger filed Form 4 for Centessa Pharmaceuticals plc (CNTA) on 01 Feb 2022.
Change
- Previous filing in this sequence was filed on 02 Nov 2021.
- Current net transaction value: +$248,754.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CNTA
transaction
Ordinary Shares
Purchase
- Transaction value
- $248,754
- Shares
- +27,500
- Change %
- Price
- $9.05
- Shares after
- 27,500
- Date
- 28 Jan 2022
- Ownership
- See footnote
- Footnotes
- F1, F2
CNTA
holding
Ordinary Shares
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 813,756
- Date
- 28 Jan 2022
- Ownership
- Direct
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
Footnote F2
Held by RxCelerate Limited ("RxCelerate"). The Reporting Person is a member of the board of directors of RxCelerate. The Reporting Person disclaims Section 16 beneficial ownership of the securities held by RxCelerate, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that he has beneficial ownership of such shares for Section 16 or any other purpose.